LONDON – Novo Holdings has inspired the formation of the second new fund in 18 months aiming to feed more capital into the commercialization of Scandinavian science, acting as cornerstone investor in Sound Bioventures Fund I. The new fund greeted the New Year with a first close of €110 million (US$124 million), to be invested in private biopharmas with late preclinical or clinical programs, primarily in rare diseases.